Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02557945 · ClinicalTrials.gov registry record · Phase 1
Gabapentin in Patients at Clinical Risk for Psychosis
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02557945 is a Phase 1 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 9 participants.
The verdict
NCT02557945, a Phase 1 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. Researchers think that treating a brain region with gabapentin (the hippocampus) may reduce the risk for developing schizophrenia.
Interventions
- DRUG Placebo
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-08-01 |
| Est. Completion | 2016-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02557945
The ClinicalTrials.gov registry entry for NCT02557945 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02557945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02557945 about?
NCT02557945 is a clinical study titled "Gabapentin in Patients at Clinical Risk for Psychosis". The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. Researchers think that treating a brain region with gabapentin (the hippocampus) may reduce the risk for developing schizophrenia.
What is the current status of trial NCT02557945?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-08-01. Estimated completion is 2016-06-12.
What interventions are being tested in trial NCT02557945?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT02557945?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.